Compare Natco Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DISHMAN PHARMA NATCO PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 15.4 25.1 61.4% View Chart
P/BV x 3.0 3.3 90.3% View Chart
Dividend Yield % 1.5 0.7 221.8%  

Financials

 NATCO PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
NATCO PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,080374 288.5%   
Low Rs671129 520.8%   
Sales per share (Unadj.) Rs592.1197.8 299.3%  
Earnings per share (Unadj.) Rs188.421.2 888.4%  
Cash flow per share (Unadj.) Rs206.334.7 594.3%  
Dividends per share (Unadj.) Rs8.252.00 412.5%  
Dividend yield (eoy) %0.90.8 118.5%  
Book value per share (Unadj.) Rs833.6179.9 463.4%  
Shares outstanding (eoy) m36.9080.69 45.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.51.3 116.2%   
Avg P/E ratio x4.611.9 39.2%  
P/CF ratio (eoy) x4.27.2 58.6%  
Price / Book Value ratio x1.11.4 75.1%  
Dividend payout %4.49.4 46.4%   
Avg Mkt Cap Rs m32,31120,306 159.1%   
No. of employees `0004.80.8 582.8%   
Total wages/salary Rs m3,2565,355 60.8%   
Avg. sales/employee Rs Th4,522.519,252.7 23.5%   
Avg. wages/employee Rs Th674.06,459.5 10.4%   
Avg. net profit/employee Rs Th1,439.02,064.1 69.7%   
INCOME DATA
Net Sales Rs m21,84815,961 136.9%  
Other income Rs m404265 152.2%   
Total revenues Rs m22,25216,226 137.1%   
Gross profit Rs m9,2844,103 226.3%  
Depreciation Rs m6621,091 60.7%   
Interest Rs m154944 16.3%   
Profit before tax Rs m8,8722,334 380.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920624 307.9%   
Profit after tax Rs m6,9521,711 406.3%  
Gross profit margin %42.525.7 165.3%  
Effective tax rate %21.626.7 81.0%   
Net profit margin %31.810.7 296.8%  
BALANCE SHEET DATA
Current assets Rs m21,30711,018 193.4%   
Current liabilities Rs m5,9209,517 62.2%   
Net working cap to sales %70.49.4 748.9%  
Current ratio x3.61.2 310.9%  
Inventory Days Days73110 66.3%  
Debtors Days Days10735 305.7%  
Net fixed assets Rs m14,98616,304 91.9%   
Share capital Rs m369161 228.6%   
"Free" reserves Rs m30,35312,907 235.2%   
Net worth Rs m30,76014,516 211.9%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m37,15129,805 124.6%  
Interest coverage x58.63.5 1,688.6%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.5 109.8%   
Return on assets %19.18.9 214.7%  
Return on equity %22.611.8 191.7%  
Return on capital %29.317.5 167.4%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m10,3224,952 208.5%   
Fx outflow Rs m2,978697 427.4%   
Net fx Rs m7,3434,255 172.6%   
CASH FLOW
From Operations Rs m4,6362,786 166.4%  
From Investments Rs m-11,155-1,529 729.6%  
From Financial Activity Rs m6,509-941 -691.6%  
Net Cashflow Rs m-18316 -5.7%  

Share Holding

Indian Promoters % 52.0 61.4 84.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.7 211.9%  
FIIs % 16.6 12.7 130.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 22.1 117.6%  
Shareholders   25,395 46,261 54.9%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  BIOCON   J.B.CHEMICALS  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 19, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS